Alerts will be sent to your verified email
Verify Email
DRREDDY
|
Dr. Reddy's Labs.
|
Zydus Lifesciences
|
Cipla
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
376.0 . | 508.0 . | 285.0 . |
|
Number of ANDA's Approved By USFDA
|
301.0 . | 435.0 . | 230.0 . |
|
Domestic Sales Growth - YoY
|
11.3 % | 12.0 % | 7.7 % |
|
Global DMFs filed
|
1379.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
7.3 % | 9.2 % | 7.8 % |
|
Financials
|
|||
|
5 yr Average ROE
|
15.68 % | 18.47 % | 13.53 % |
|
5yr average Equity Multiplier
|
1.41 | 1.52 | 1.22 |
|
5yr Average Asset Turnover Ratio
|
0.74 | 0.66 | 0.77 |
|
5yr Avg Net Profit Margin
|
15.18 % | 19.02 % | 14.55 % |
|
Price to Book
|
2.97 | 4.05 | 3.38 |
|
P/E
|
26.85 | 21.8 | 29.99 |
|
5yr Avg Cash Conversion Cycle
|
74.48 Days | -84.89 Days | -6.65 Days |
|
Inventory Days
|
76.14 Days | 36.38 Days | 57.59 Days |
|
Days Receivable
|
95.44 Days | 36.93 Days | 52.05 Days |
|
Days Payable
|
102.6 Days | 160.15 Days | 107.59 Days |
|
5yr Average Interest Coverage Ratio
|
35.66 | 30.19 | 68.84 |
|
5yr Avg ROCE
|
21.82 % | 19.65 % | 19.16 % |
|
5yr Avg Operating Profit Margin
|
23.61 % | 24.4 % | 22.76 % |
|
5 yr average Debt to Equity
|
0.12 | 0.17 | 0.02 |
|
5yr CAGR Net Profit
|
23.71 % | 16.23 % | 9.04 % |
|
5yr Average Return on Assets
|
11.24 % | 12.22 % | 11.12 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
26.63 % | 75.0 % | 29.21 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.07 % | 0.02 % | -4.34 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
3.32 % | -0.71 % | 3.66 % |
|
Dr. Reddy's Labs.
|
Zydus Lifesciences
|
Cipla
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|